Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production

2nd Nov 2023 14:34

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Taseko Mines Ltd - North America-focused mining company - Copper production for third quarter of 2023 totals 35.4 million pounds, up 7.1% from 28.3 million last year. 32.1 million pounds sold, up 5.4% from 26.7 million. Production for nine months ended September 30 totals 88.5 million pounds, up 18% from 70.3 million. Revenue for the quarter increases 60% to CAD143.8 million from CAD89.7 million. Adjusted Ebitda up 84% to CAD62.7 million from CAD34.0 million. Company swings to GAAP net income of CAD871,000 from a CAD23.5 million loss. Says cash balance at September 30 was CAD82 million.

----------

Henderson International Income Trust PLC - London-based investment company - NAV per share at August 31 is 175.7 pence, down from 181.5p at the same time in 2022. NAV total return for year ended August 31 is positive 1.4%, down from 6.3% the previous year. Pretax net return decreases to GBP5.2 million from GBP15.2 million. Company delivers GBP9.0 million investments loss following GBP1.8 million gain. Declares 1.92 pence fourth interim dividend regardless, up from 1.85p last year. Total dividend increases 3.0% to 7.47p. Chair Richard Hills says: "We cannot control the macroeconomic background but we can maintain and follow the company's existing strategy of identifying companies that have the capacity to grow their earnings and dividends over the medium to long term."

----------

Kanabo Group PLC - London-based patient focused healthcare technology and cannabis company - Inks deal with Wokingham, England-based cannabis manufacturer British Cannabis to supply CBD to patients via prescription. Company says the deal will allow doctors to prescribe pharmacy-grade CBD products from the 'CBD by British Cannabis' range via Treat It, Kanabo's online pain management clinic. Kanabo also says that from this month, Treat It will be included in British Cannabis's online medicinal cannabis app Canndr, which enables patients to select and review cannabis medicines, gain consultancy advice and select prescribing clinics. Kanabo Chief Executive Officer Avihu Tamir says: "This partnership is just the beginning, and we hope to announce more expansive collaborations in due course."

----------

Ocean Harvest Technology Group PLC - Theale, England-headquartered producer of seaweed-based ingredients for animal feed - Announces results of study assessing its OceanFeed Poultry product in meat chickens with necrotic enteritis, a disease caused by the overgrowth of clostridium perfringens in a poultry bird's gut. OceanFeed products aim to bind this pathogen. Study was conducted at the Southern Poultry Research Group in Georgia, US. Company says out of 200 chickens, mortality in the group consuming OceanFeed Poultry "reduced significantly" to 33% from 49%. This group also experienced enhanced weight gain and improved intenstinal lesion scores. Company says data "enhances the use case of OFP in the global poultry industry and will be useful data in discussions with customers currently using and/or looking to use OFP."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Announces strategic collaboration with fellow Oxfordian data company Arcturis Data Ltd. Deal will integrate Arcturis's Rea-World Evidence platform and analytical expertise with e-therapeutics's HepNet computational biology platform. HepNet will be used to analyse RWE's output "to drive the discovery and development of innovative RNAi medicines for the treatment of [nonalcoholic steatohepatitis] and related disorders." e-therapeutics retains exclusive rights to nominate novel gene targets to prosecute genetic medicines using its GalOmic platform.

----------

StreaksAI PLC - London-based provider of artificial intelligence-based conversational technologies - Launches "highly personalised" AI chatbot service Streaks Companion, which allows for "sophisticated humanlike companionship, mentorship and digital assistant services." Chatbots are designed for private long-term conversations using Natural Language Processing generators including GPT-4. Says companionship "can either be romantic or platonic, designed to increase users' confidence in navigating real-life relationships, it also offers a secure environment for users to build relationship skills and develop new romantic experiences." Users will pay GBP4.99 per 100 interactions. Company also says it has seen promising levels of early sign-ups for its new Streaks Idols service, which launched in late September and currently has 9,135 registered users.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to [email protected]

Copyright 2023 Alliance News Ltd. All Rights Reserved.

FTSE 100 Latest
Value7,706.28
Change21.79